30 results about "Pneumococcal vaccine" patented technology

The present invention relates to new pneumococcal vaccines. The invention also relates to vaccination of subjects, in particular immunocompromised subjects, against pneumococcal infections using said novel pneumococcal vaccines.

The invention relates to bacterial choline binding proteins (CBPs) which bind choline. Such proteins are particularly desirable for vaccines against appropriate strains of Gram positive bacteria, particularly streptococcus, and more particularly pneumococcus. Also provided are DNA sequences encoding the bacterial choline binding proteins or fragment thereof, antibodies to the bacterial choline binding proteins, pharmaceutical compositions comprising the bacterial choline binding proteins, antibodies to the bacterial choline binding proteins suitable for use in passive immunization, and small molecule inhibitors of choline binding protein mediated adhesion. Methods for diagnosing the presence of the bacterial choline binding protein, or of the bacteria, are also provided. In a specific embodiment, a streptococcal choline binding protein is an enolase, which demonstrates strong affinity for fibronectin.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention thereforerelates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

This invention relates to a live mutated strain of S. pneumoniae which is incapable of expressing polysaccharide capsule, while still capable of colonizing the nasopharynx of the subject.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

Immunogenic composition are provided comprising PnCo and/or GlpO polypeptides identified as being preferentially expressed during the virulent phase of an infection related to streptococcal bacteria. The compositions can be used for eliciting immune response against streptococcal infections, such as against infections caused by S. pneumoniae.

The invention relates to a method for preparing pneumococcal capsular polysaccharide and a pneumococcal vaccine. A method of making a pneumococcal capsular polysaccharide comprises providing a pneumococcal lysate of a selected serotype; removing proteins and nucleic acids from the lysate, the removal of proteins and the removal of nucleic acids being performed out of order in separate steps; the method for removing the protein comprises the following steps: I) mixing a sample to be treated with sodium deoxycholate to enable the pH value of the mixed system to be 3-6, centrifuging to obtain supernate, and adjusting the pH value of the supernate to be 6-8 to obtain first supernate; iI) removing sodium deoxycholate in the first supernate; the method for removing the nucleic acid comprises the following steps: A) mixing a sample to be treated with divalent salt to enable the pH value of the mixed system to be 1-4, centrifuging to obtain supernate, and adjusting the pH value of the supernate to be 6-8 to obtain second supernate; and B) removing the divalent salt added in the step A) in the second supernatant. The method is simple and ingenious, and an excellent pneumococcus capsular polysaccharide purification effect is achieved.

The invention discloses a streptococcus pneumoniae vaccine and a preparation method thereof. The streptococcus pneumoniae vaccine is prepared by mixing S3CS recombinant antigens or mutant protein antigens with additives. The vaccine can be applied to immunity; the protection of organisms on streptococcus pneumonia can be improved; a specific antibody can be generated. A preparation method of the vaccine is simple; the requirements of large-scale industrial production can be met.